Canaccord Boosts PT on InterMune (ITMN) on Positive ASCEND Phase 3 Expectations
Tweet Send to a Friend
Canaccord Genuity maintains its Buy rating on InterMune (Nasdaq: ITMN) and raises its price target from $17 up to $22.
This article: 214 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 214 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
